SignalXSignalX

AXSM Axsome Therapeutics, Inc.

Q3 2025 10-Q
Filed: Nov 3, 2025Period ending Sep 30, 2025
Health Care
Pharmaceutical PreparationsSEC EDGAR
Axsome Therapeutics, Inc. Overview

Axsome Therapeutics, Inc. (AXSM) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 3, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q3 2025 10-Q

Risk Factors

  • • New risk: Blackstone Loan Agreement with $570M facility triggered by May 8, 2025 closing, includes covenants restricting operations and $30M minimum liquidity covenant
  • • Most materially updated risk: U.S. political uncertainty with 2025 federal government shutdown and 100% tariff on branded pharmaceuticals starting October 1, 2025, may disrupt operations
+3 more insights

Quarterly Financial Summary
XBRL

Revenue

$171M

▲ +63.2% YoY▲ +14.0% QoQ

Net Income

-$47M

▲ +26.9% YoY▲ +1.6% QoQ

Operating Margin

-27.0%

▲ +3281bp YoY▼ -250bp QoQ

Net Margin

-27.6%

▲ +3404bp YoY▲ +435bp QoQ

ROE

-64.1%

Total Assets

$669M

EPS (Diluted)

$-0.95

▲ +29.1% YoY▲ +1.0% QoQ

Operating Cash Flow

$1M

▲ +105.6% YoY▲ +103.2% QoQ

Source: XBRL data from Axsome Therapeutics, Inc. Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.

Get deeper insights on Axsome Therapeutics, Inc.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.